Amitiza (大腸躁鬱症治療藥) - 2023年前的預測與市場分析
Amitiza (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 45 Pages
|Amitiza (大腸躁鬱症治療藥) - 2023年前的預測與市場分析 Amitiza (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023|
|出版日期: 2014年12月31日||內容資訊: 英文 45 Pages||
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Amitiza (lubiprostone) is indicated for the treatment of IBS-C in women 18 years of age and older, but only in the US. This product was developed by Sucampo Pharmaceuticals and Takeda, and initially gained approval in the US in 2006 for the treatment of chronic idiopathic constipation (CIC) in adults. In 2008, Amitiza gained a label expansion from the Food and Drug Administration (FDA) for the treatment of IBS-C in women of 18 years of age and older.